Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

Cuban annual raw sugar production will fall below 200,000 metric tons in 2025 for the first time since the 19th century, ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

Vikrant Shrotriya said Human Mixtard is not being discontinued in India and will be supplied in vial presentation ...

A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...

The REAL8 basket study showed Sogroya (somapacitan) was non-inferior to Norditropin (somatropin) in improving yearly growth ...

Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best pharma stocks to invest in now amid the domestic ...

The best metric is not weight, but a particularly toxic kind of fat.

Scientists herald 150 new jabs and pills to tackle obesity going through the research pipeline - but issue urgent warning to ...

With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk is making good on plans to boost its profile in ...

The Tata-Cornell Institute project aims to strengthen Indian food value chains for climate resilience and nutritious diets.